Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2

Kevin Barley; Larysa Sanchez; Hearn J. Cho; Samir Parekh; Deepu Madduri; Joshua Richter; Luis Isola; Talia Goldstein; Amishi Dhadwal; Katarzyna Zarychta; Gillian Morgan Sanchez; Donna Catamero; Daniel Verina; Erika Florendo; Moon hee Yum; Lisa La; Jude Gullie; Elaine Chan; Sundar Jagannath; Ajai Chari

doi:10.1002/ajh.25695

Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m²

Kevin Barley, Larysa Sanchez, Hearn J. Cho, Samir Parekh, Deepu Madduri, Joshua Richter, Luis Isola, Talia Goldstein, Amishi Dhadwal, Katarzyna Zarychta, Gillian Morgan Sanchez, Donna Catamero, Daniel Verina, Erika Florendo, Moon hee Yum, Lisa La, Jude Gullie, Elaine Chan, Sundar Jagannath, Ajai Chari

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E51-E54
Journal	American Journal of Hematology
Volume	95
Issue number	2
DOIs	https://doi.org/10.1002/ajh.25695
State	Published - 1 Feb 2020

Access to Document

10.1002/ajh.25695

Cite this

Barley, K., Sanchez, L., Cho, H. J., Parekh, S., Madduri, D., Richter, J., Isola, L., Goldstein, T., Dhadwal, A., Zarychta, K., Sanchez, G. M., Catamero, D., Verina, D., Florendo, E., Yum, M. H., La, L., Gullie, J., Chan, E., Jagannath, S., & Chari, A. (2020). Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m². American Journal of Hematology, 95(2), E51-E54. https://doi.org/10.1002/ajh.25695

@article{ddc659e8cd4b4b2ca3679f0d77a6f74a,

title = "Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2",

author = "Kevin Barley and Larysa Sanchez and Cho, {Hearn J.} and Samir Parekh and Deepu Madduri and Joshua Richter and Luis Isola and Talia Goldstein and Amishi Dhadwal and Katarzyna Zarychta and Sanchez, {Gillian Morgan} and Donna Catamero and Daniel Verina and Erika Florendo and Yum, {Moon hee} and Lisa La and Jude Gullie and Elaine Chan and Sundar Jagannath and Ajai Chari",

note = "Funding Information: We thank the patients and their families for their willingness to participate in clinical trials. This work was funded and supported by Onyx Pharmaceuticals, which was acquired by Amgen in August 2013. ",

year = "2020",

month = feb,

day = "1",

doi = "10.1002/ajh.25695",

language = "English",

volume = "95",

pages = "E51--E54",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "2",

}

Barley, K, Sanchez, L, Cho, HJ , Parekh, S , Madduri, D , Richter, J , Isola, L, Goldstein, T, Dhadwal, A, Zarychta, K, Sanchez, GM, Catamero, D, Verina, D, Florendo, E, Yum, MH, La, L, Gullie, J, Chan, E, Jagannath, S & Chari, A 2020, 'Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m²', American Journal of Hematology, vol. 95, no. 2, pp. E51-E54. https://doi.org/10.1002/ajh.25695

TY - JOUR

T1 - Recapturing disease response

T2 - A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2

AU - Barley, Kevin

AU - Sanchez, Larysa

AU - Cho, Hearn J.

AU - Parekh, Samir

AU - Madduri, Deepu

AU - Richter, Joshua

AU - Isola, Luis

AU - Goldstein, Talia

AU - Dhadwal, Amishi

AU - Zarychta, Katarzyna

AU - Sanchez, Gillian Morgan

AU - Catamero, Donna

AU - Verina, Daniel

AU - Florendo, Erika

AU - Yum, Moon hee

AU - La, Lisa

AU - Gullie, Jude

AU - Chan, Elaine

AU - Jagannath, Sundar

AU - Chari, Ajai

N1 - Funding Information: We thank the patients and their families for their willingness to participate in clinical trials. This work was funded and supported by Onyx Pharmaceuticals, which was acquired by Amgen in August 2013.

PY - 2020/2/1

Y1 - 2020/2/1

UR - http://www.scopus.com/inward/record.url?scp=85077002349&partnerID=8YFLogxK

U2 - 10.1002/ajh.25695

DO - 10.1002/ajh.25695

M3 - Letter

C2 - 31814152

AN - SCOPUS:85077002349

SN - 0361-8609

VL - 95

SP - E51-E54

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 2

ER -